Comparative Pharmacology
Head-to-head clinical analysis: ANUSOL HC versus LOCOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANUSOL HC versus LOCOID.
ANUSOL HC vs LOCOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone, a corticosteroid, binds to glucocorticoid receptors, inhibiting phospholipase A2 activity and reducing prostaglandin and leukotriene synthesis. It also suppresses cytokine production and inflammatory cell migration, leading to decreased edema, erythema, and pruritus in anorectal tissues.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Apply a thin layer to the affected area rectally 2 to 4 times daily, or after each bowel movement, for up to 7 days. Each application should not exceed 1 gram.
Topical: Apply a thin layer to affected area once or twice daily. Maximum: 30-60 g per week. Not for use >2 consecutive weeks or on >50% of body surface.
None Documented
None Documented
Terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours (range 1-3 h) in adults; clinical effect outlasts half-life due to intracellular receptor-mediated action.
Terminal elimination half-life: 30-40 hours; clinically significant for once-daily dosing and prolonged action
Renal (primarily as metabolites) >80%; fecal ~15%; <2% unchanged in urine due to extensive hepatic metabolism. Biliary excretion is negligible.
Renal (approximately 60-70%) as conjugated metabolites; biliary/fecal (approximately 20-30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid